These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8718425)

  • 21. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.
    Chen YM; Perng RP; Lee YC; Shih JF; Lee CS; Tsai CM; Whang-Peng J
    Ann Oncol; 2002 Jan; 13(1):108-15. PubMed ID: 11863090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-agent gemcitabine versus cisplatin/etoposide in patients with inoperable, locally advanced, or metastatic non-small cell lung cancer.
    Manegold C
    Semin Oncol; 1998 Aug; 25(4 Suppl 9):18-22. PubMed ID: 9728580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer.
    Lees M; Aristides M; Maniadakis N; McKendrick J; Botwood N; Stephenson D
    Pharmacoeconomics; 2002; 20(5):325-37. PubMed ID: 11994042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).
    Reaume MN; Leighl NB; Mittmann N; Coyle D; Hirsh V; Seymour L; Tu D; Shepherd FA; Graham B; Gridelli C; Perrone F; Di Maio M; Bradbury PA; Evans WK
    Lung Cancer; 2013 Oct; 82(1):115-20. PubMed ID: 23962449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II trial of gemcitabine and ifosfamide in non-small cell lung cancer.
    Gatzemeier U; Manegold C; Eberhard W; Wilke HJ; Chomy F; Chomy P; Khayat D; Blatter J; Seeber S; Drings P
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-36-S8-38. PubMed ID: 9207315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer.
    Baka S; Manegold C; Buchholz E; Schott-von-Römer K; Lorigan P; Nagel S; Blackhall F; Aschroft L; Thatcher N
    Lung Cancer; 2006 Aug; 53(2):165-70. PubMed ID: 16787686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States.
    Lang K; Marciniak MD; Faries D; Stokes M; Buesching D; Earle C; Treat J; Babineaux S; Morissette N; Thompson D
    Value Health; 2009 Jun; 12(4):481-8. PubMed ID: 18980633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.
    Noble S; Goa KL
    Drugs; 1997 Sep; 54(3):447-72. PubMed ID: 9279506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
    Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer.
    Neymark N; Lianes P; Smit EF; van Meerbeeck JP
    Pharmacoeconomics; 2005; 23(11):1155-66. PubMed ID: 16277550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Front-line weekly chemotherapy with gemcitabine for unfit patients with non-small cell lung cancer (NSCLC).
    Ferrigno D; Buccheri G;
    Lung Cancer; 2004 Sep; 45(3):373-80. PubMed ID: 15301878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gemcitabine as single agent chemotherapy in elderly patients with stages III-IV non-small cell lung cancer (NSCLC): a phase II study.
    Bianco V; Rozzi A; Tonini G; Santini D; Magnolfi E; Vincenzi B; D'Angelillo R; Marchei P
    Anticancer Res; 2002; 22(5):3053-6. PubMed ID: 12530041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer.
    Chen YM; Perng RP; Yang KY; Liu TW; Tsai CM; Ming-Liu J; Whang-Peng J
    Chest; 2000 Jun; 117(6):1583-9. PubMed ID: 10858387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Chemotherapy of stage IV non-small-cell lung cancer: contribution of gemcitabine].
    Souquet PJ; Gérinière L
    Rev Pneumol Clin; 2000 Nov; 56(5):315-9. PubMed ID: 11139761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
    Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G;
    Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Current status and future directions of gemcitabine in the treatment of non-small cell lung cancer and pancreatic cancer].
    Yokoyama A
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1294-300. PubMed ID: 10945029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of gemcitabine with concurrent radiotherapy on stage III,inoperable non-small cell lung cancer].
    Li GZ; Zhang SH; Zhang Z; Wang RL
    Ai Zheng; 2007 Dec; 26(12):1377-80. PubMed ID: 18076806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer.
    Lee DH; Han JY; Cho KH; Pyo HR; Kim HY; Yoon SJ; Lee JS
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1037-44. PubMed ID: 16024178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.
    Cardenal F; López-Cabrerizo MP; Antón A; Alberola V; Massuti B; Carrato A; Barneto I; Lomas M; García M; Lianes P; Montalar J; Vadell C; González-Larriba JL; Nguyen B; Artal A; Rosell R
    J Clin Oncol; 1999 Jan; 17(1):12-8. PubMed ID: 10458212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.
    Takeda AL; Jones J; Loveman E; Tan SC; Clegg AJ
    Health Technol Assess; 2007 May; 11(19):iii, ix-xi, 1-62. PubMed ID: 17462169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.